Open in interactive viewer → charts, metric popovers & call review

EyePoint Cut 53% of Its Staff to Buy Time It Doesn't Quite Have

Two failed Phase III wet AMD trials, a $30 million market cap, and a DME readout scheduled for the exact quarter the cash runs out
EYPT · Earnings Call · 2026-11-12

The failure, and the arithmetic that followed

EyePoint's third quarter was defined by an absence. Both Phase III wet AMD studies of DURAVYU — LUGANO and LUCIA — missed their primary endpoint in the full analysis population, the company disclosed in August and October. The tape has already rendered its verdict: the shares are down roughly 97% over the last ninety trading days, off a July peak of $14.84, leaving a company with a market capitalization near $30 million. This is not a drawdown. It is a reckoning. Management's response was fast and brutal. The wet AMD program is discontinued, headcount cut by roughly 53%, and a $30 million annualized savings target set. What remains is a single asset in a single indication: DURAVYU in diabetic macular edema, via the COMO and CAPRI trials, with top-line data guided to early in the fourth quarter of 2027. The keyword record maps the pivot precisely. This quarter's top-ranked company theme is DME patient, with non inferiority and primary endpoint close behind — while the wet AMD vocabulary is in open decline: "Lugano," "LUCIA trial," and "wet AMD trial" all sit among the quarter's biggest keyword fallers. The company is no longer a wet AMD story that also happens to have a DME program. It is a DME company with a scar.

The runway is the whole investment case now

George Elston put the cash position at approximately $118 million as of September 30, funding operations "into late Q3 2027." The DME readouts are guided to "early in the fourth quarter of 2027." That is not a margin of safety; it is a rounding error against a clinical calendar. When Yigal Nochomovitz of Citigroup asked the obvious question, the CFO's answer was candid to the point of discomfort:

I think as we said on the call, as part of the strategic adjustment of the organization, we have and continue to actively review forward obligations and for additional cost reductions and cash conservation as we focus on DME. And where we sit today, we just about get there... From a management perspective, our plan is to not run out of cash and to make sure that we get the organization and the company to and through DME data next year.

George Elston, Chief Financial Officer · 2026-11-12
That is a plan, not a financing. And the cash runway theme is not new — it has been a recurring EyePoint keyword since at least late 2025, when it ranked ninth on the call. What has changed is the denominator: the burn has been rising even as the pipeline narrowed. Research and development expense reached $84 million with a 51% year-over-year increase, and operating income has deteriorated to -$97 million. The runway, measured in quarters, has been shrinking steadily. With no futility analysis planned for the DME studies — Ramiro Ribeiro confirmed there will be no interim peek — there is no scheduled moment between now and late 2027 at which management learns anything, or tells anyone anything, before the money and the data collide.

What they stopped saying — and what quietly came back

The most instructive contrast is against EyePoint's own prior language. In March, Jay Duker described the regulatory strategy in terms that now read as tragic bravado: “We think our pathway is derisked. We have taken the noninferiority approach, which is, you know, the approach essentially that five of the last approvals have taken.” — Jay Duker, President and Chief Executive Officer · 2026-03-04 In November 2025 he was more specific: “Based on our strong Phase II data, we would expect non-inferiority to the on-label Eylea control with continued safety.” — Jay Duker, President and Chief Executive Officer · 2025-11-05 That expectation is precisely what failed to materialize across roughly 450 patients. Two things have now dropped out of the narrative. First, the wet AMD program itself — gone in a sentence. Second, "single trial" regulatory chatter, which appeared as a company keyword theme in early 2026 and which Duker explicitly dismissed as offering "no particular advantage." Yet on this call he resurrected the wet AMD concept in a different form: “should we be able to identify a subgroup of patients or biomarker from the wet AMD data that might suggest the ability to have a successful trial, the possibility of trying to get approval in wet AMD again. So we are leaving no stone unturned here.” — Jay Duker, President and Chief Executive Officer · 2026-11-12 A subgroup of patients hunt is the oldest salvage maneuver in biotechnology, and Duker was careful to promise nothing — no elaboration until the analysis is complete. The one durable asset he can point to is the safety database: greater than 300 patients with two years of exposure at the end of the DME program, which he argued would support a label for reinjection indefinitely. Safety with repeat dosing is the only part of the wet AMD investment that has not been written off.

The needle they are threading in the DME protocol

The scientific case for DME is genuinely different from wet AMD, and the call made it well: DME is an inflammatory, blood-retinal-barrier disease with elevated IL-6, and vorolanib inhibits JAK1 downstream of IL-6 in addition to VEGF and PDGF. The VERONA data — 73% of DURAVYU patients supplement-free at week 24 versus 50% of controls — is the evidence base. But the protocol change is where the story turns. EyePoint amended the rescue threshold: patients now qualify for a supplement injection on a decline of more than five letters rather than ten. Ramiro Ribeiro framed it as protective: “We believe that those changes have the potential to preserve BCVA and help us, of course, with the primary endpoint.” — Ramiro Ribeiro, Chief Medical Officer · 2026-11-12 That is honest — and it is also the opposite direction from the tightening narrative management touted for wet AMD in May: “We do anticipate that the supplementation rates in the Phase III trials will be less than what we saw in the Phase II for several reasons, again, due to the tightening of the supplement criteria.” — Jay Duker, President and Chief Executive Officer · 2026-05-06 Looser rescue protects the vision endpoint while diluting the treatment-burden story that was supposed to be the commercial differentiator. Add the asymmetric design — five on-label Eylea loading doses in the control arm versus two shams in the DURAVYU arm — and the non-inferiority hurdle is, as Steven Seedhouse of Cantor pressed, steeper than it was in wet AMD.

The read

EyePoint is now a binary, single-asset, sub-$50 million market cap with a cash balance that expires roughly one quarter before its only remaining catalyst. Management has multiple levers — further cost cuts, business development, financings — and no commitment beyond a stated intention. The DME thesis is scientifically coherent and the safety package is real, but the market has stopped paying for coherence. What it will pay for, in late 2027 or via a partnership before then, is data. Until something is signed, this is a company spending its last dollars to find out whether the second disease behaves differently from the first.